A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second ‐ and third‐generation tyrosine kinase inhibitors

Cancer Medicine, EarlyView.

Source: Cancer Medicine - October 15, 2018 Category: Cancer & Oncology Authors: Alejandro Zulbaran ‐Rojas, Huei‐Kan Lin, Qiuling Shi, Loretta A. Williams, Binsah George, Guillermo Garcia‐Manero, Elias Jabbour, Susan O’Brien, Farhad Ravandi, William Wierda, Zeev Estrov, Gautam Borthakur, Tapan Kadia, Charles Cleel Source Type: research